Avalglucosidase alfa 10 mg/mL Solution, 72500 mL — NDC 58468-5006-1 (Billing 58468-5006-01)
This is a package of 72,500 mL of Avalglucosidase alfa 10 mg/mL Solution from Genzyme Corporation, marketed since Jun 2021 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 58468-5006-1 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 58468 labeler · 5006 product · 1 package
- Package marketed since
- Jun 8, 2021
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 5846850061 8
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
This is a solution containing avalglucosidase alfa, an enzyme replacement therapy typically used to treat Pompe disease, a rare genetic disorder in which the body cannot break down a sugar called glycogen. Avalglucosidase alfa is designed to replace or supplement the missing or deficient enzyme (acid alpha-glucosidase) in patients with this condition. The product is marked as a drug for further processing, meaning it is intended for use in the preparation of finished pharmaceutical formulations rather than direct patient use.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 8, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 58468-5006-01 You're viewing this Main listing | 72500 mL in 1 BAG | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Avalglucosidase alfa 10 mg/mLthis 58468-5006-01 | Genzyme | 72500 ml | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Genzyme Corporation labeler code 58468
- Qfitlia fitusiran 20 mg/.2mL Injection, Solution NDC 58468-0347-1
- Qfitlia fitusiran 50 mg/.5mL Injection, Solution NDC 58468-0348-1
- Campath ALEMTUZUMAB 30 mg/mL Injection NDC 58468-0357-1
- Nexviazyme avalglucosidase alfa-ngpt 100 mg/10mL Injection, Powder, Lyophilized, For Solution NDC 58468-0426-1
- Cerezyme IMIGLUCERASE 40 U/mL Injection, Powder, Lyophilized, For Solution NDC 58468-4663-1
- Alglucosidase alfa 5 mg/mL Solution NDC 58468-5005-1
- IMIGLUCERASE 40 U/mL Injection, Powder, Lyophilized, For Solution NDC 58468-5010-1
- AVALGLUCOSIDASE ALFA 100 mg/10mL Injection, Powder, Lyophilized, For Solution NDC 58468-5011-1
- THYROTROPIN ALFA .9 mg/mL Injection, Powder, Lyophilized, For Solution NDC 58468-5015-1
- LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN 25 mg/5mL Injection, Powder, For Solution NDC 58468-5025-1
- AGALSIDASE BETA 5 mg/mL Injection, Powder, Lyophilized, For Solution NDC 58468-5030-1
- Dupilumab 150 mg/mL Solution NDC 58468-5150-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Reported adverse events (FAERS)
Top reported reactions
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Genzyme Corporation supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |